User login
Key clinical point: The combination of immune checkpoint inhibitors (ICIs) with regorafenib showed promising efficacy in chemotherapy-refractory microsatellite stable (MSS) colorectal cancer (CRC).
Major finding: Overall, 5% and 45% of patients achieved partial response and stable disease as the best response, respectively. The median overall survival and progression-free survival (PFS) were 17.3 months (95% CI, 11.3-not reached) and 3.1 months (95% CI, 2.3-4.2), respectively, with 13% of patients achieving PFS of ≥6 months. Grade 3 or higher treatment-related adverse events were reported by 19% of patients.
Study details: Findings are from a retrospective analysis of 84 patients with chemotherapy-refractory advanced or metastatic MSS CRC who received at least 1 dose of ICIs combined with regorafenib.
Disclosures: This work was supported by grants from the National Natural Science Foundation of China and CAMS Innovation Fund for Medical Sciences. The authors declare no conflict of interests.
Source: Yang K et al. Cancer Immunol Immunother. 2021 Oct 24. doi: 10.1007/s00262-021-03083-3.
Key clinical point: The combination of immune checkpoint inhibitors (ICIs) with regorafenib showed promising efficacy in chemotherapy-refractory microsatellite stable (MSS) colorectal cancer (CRC).
Major finding: Overall, 5% and 45% of patients achieved partial response and stable disease as the best response, respectively. The median overall survival and progression-free survival (PFS) were 17.3 months (95% CI, 11.3-not reached) and 3.1 months (95% CI, 2.3-4.2), respectively, with 13% of patients achieving PFS of ≥6 months. Grade 3 or higher treatment-related adverse events were reported by 19% of patients.
Study details: Findings are from a retrospective analysis of 84 patients with chemotherapy-refractory advanced or metastatic MSS CRC who received at least 1 dose of ICIs combined with regorafenib.
Disclosures: This work was supported by grants from the National Natural Science Foundation of China and CAMS Innovation Fund for Medical Sciences. The authors declare no conflict of interests.
Source: Yang K et al. Cancer Immunol Immunother. 2021 Oct 24. doi: 10.1007/s00262-021-03083-3.
Key clinical point: The combination of immune checkpoint inhibitors (ICIs) with regorafenib showed promising efficacy in chemotherapy-refractory microsatellite stable (MSS) colorectal cancer (CRC).
Major finding: Overall, 5% and 45% of patients achieved partial response and stable disease as the best response, respectively. The median overall survival and progression-free survival (PFS) were 17.3 months (95% CI, 11.3-not reached) and 3.1 months (95% CI, 2.3-4.2), respectively, with 13% of patients achieving PFS of ≥6 months. Grade 3 or higher treatment-related adverse events were reported by 19% of patients.
Study details: Findings are from a retrospective analysis of 84 patients with chemotherapy-refractory advanced or metastatic MSS CRC who received at least 1 dose of ICIs combined with regorafenib.
Disclosures: This work was supported by grants from the National Natural Science Foundation of China and CAMS Innovation Fund for Medical Sciences. The authors declare no conflict of interests.
Source: Yang K et al. Cancer Immunol Immunother. 2021 Oct 24. doi: 10.1007/s00262-021-03083-3.